Research and Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenue by Collaboration Partners

The following table summarizes the revenue by collaboration partners:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
	(in thousands)				(in thousands)
AbbVie	$	1,382	$	10,763	$	4,330	$	13,434
Amgen		222		1,597		1,257		2,852
BMS		7,409		8,242		32,911		16,410
ImmunoGen		-		736		-		1,471
Pfizer		-		-		-		1,355
Total Revenue	$	9,013	$	21,338	$	38,498	$	35,522

Summary of Contracts Assets and Liabilities

The following table presents changes in the Company’s total contract liabilities during the six months ended June 30, 2019:

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
	(in thousands)
Contract liabilities:
Deferred revenue	$	277,980	$	10,000	$	(38,470	)	$	249,510